# Baxter International Inc. (BAX) Stock Analysis: Navigating Challenges with a 9.31% Potential Upside

- Link: https://www.directorstalkinterviews.com/baxter-international-inc-bax-stock-analysis-navigating-challenges-with-a-9-31-potential-upside/4121240019
- Published: 2026-02-16T11:25:57+00:00
- Author: Madison Wilson

Baxter International Inc. (NYSE: BAX) stands as a stalwart in the healthcare sector,
offering a diverse portfolio of medical instruments and supplies. Headquartered 
in Deerfield, Illinois, and with a market capitalization of $10.18 billion, Baxter
operates globally, delivering essential healthcare products and services to a wide
array of medical environments, from hospitals to home care settings.

As of the latest trading session, Baxter’s stock is priced at $19.79, reflecting
a modest change of 0.06%. This places the stock near the lower end of its 52-week
range of $17.42 to $36.57, suggesting a potentially undervalued opportunity for 
investors looking to capitalize on its recovery.

A glance at Baxter’s valuation metrics reveals some critical insights. The absence
of a trailing P/E ratio and a PEG ratio indicates that the company is currently 
not profitable on a per-share basis, as evidenced by the negative EPS of -1.75. 
However, the forward P/E of 9.52 implies that analysts expect a turnaround in the
company’s earnings, presenting a more optimistic view of its future profitability.

Revenue growth of 8.00% underscores Baxter’s ability to generate increased sales,
yet challenges remain, as highlighted by a return on equity of -13.71%. This negative
ROE indicates that the company is currently struggling to generate profit from its
equity. Nevertheless, the substantial free cash flow of over $2.4 billion provides
a cushion for Baxter to invest in growth initiatives and navigate financial headwinds.

Baxter’s dividend yield of 2.63% may attract income-focused investors, although 
caution is warranted given the payout ratio of 307.69%. This ratio suggests that
the company is distributing more in dividends than it earns, a situation that is
unsustainable in the long term without improvements in profitability.

Analyst ratings highlight a cautious optimism surrounding Baxter’s stock. Out of
the total ratings, three analysts recommend a ‘Buy’, thirteen suggest a ‘Hold’, 
and one advises a ‘Sell’. The average target price of $21.63 indicates a potential
upside of 9.31%, providing some encouragement to investors considering a position
in Baxter.

From a technical perspective, investors should note the stock’s relative strength
index (RSI) of 79.32, which suggests that the stock is currently overbought. This
could imply a potential pullback in the near term. Additionally, the stock is trading
below its 200-day moving average of $24.00, but slightly above the 50-day moving
average of $19.74, indicating recent momentum in its favor.

Baxter’s global reach and diversified product offerings position it well in the 
competitive healthcare landscape. The company’s operations span across key regions,
including Eastern and Western Europe, Asia, and the Americas, offering resilience
against localized market fluctuations.

For investors, Baxter presents a complex but intriguing case. The company’s robust
free cash flow and potential for earnings recovery offer a silver lining amid current
profitability challenges. As healthcare continues to be a critical industry worldwide,
Baxter’s strategic initiatives and broad product portfolio may pave the way for 
future growth, making it a stock to watch closely.

Share on: